Repligen | RGEN - Actif À Court Terme





Actif À Court Terme Changement Date
Agilent USD 4.69B 70M 2026-06
Align Technology USD 2.66B 7.62M 2026-06
Bio Techne USD 744.4M 56.35M 2026-06
BioMarin Pharmaceutical USD 3.97B 633.45M 2026-06
Bristol-Myers Squibb USD 28.58B 1.37B 2026-06
Bruker USD 2.22B 121.4M 2026-06
Charles River Laboratories USD 1.53B 40.3M 2026-06
Danaher USD 13.38B 554M 2026-06
Dentsply International USD 1.93B 83M 2026-06
General Electric Aerospace USD 39.7B 664M 2026-06
Henry Schein USD 4.6B 104M 2026-06
Illumina USD 2.83B 96M 2026-06
IQVIA Holdings USD 6.23B 6M 2026-06
Mettler Toledo International USD 1.35B 15.48M 2026-06
Myriad Genetics USD 289M 23.8M 2026-06
OraSure Technologies USD 222.94M 17.84M 2026-06
Pacific Biosciences Of California USD 338.64M 30.88M 2026-06
Pfizer USD 41.36B 1.46B 2026-06
Repligen USD 1.2B 39.19M 2026-06
Revvity USD 2.3B 169.4M 2026-06
Standard Biotools USD 521.45M 67.19M 2026-03
Thermo Fisher Scientific USD 23.36B 1.05B 2026-06
Waters USD 3.9B 186M 2026-06
West Pharmaceutical Services USD 1.81B 19.3M 2026-06